Tokyo University And IAVI Plan Phase I Test Of AIDS Vaccine
This article was originally published in PharmAsia News
Tokyo University's Institute of Medical Science and the International Aids Vaccine Initiatives are jointly planning Phase I testing of an AIDS vaccine, IMS Professor Tetsuro Matano announced at the Tokyo Vaccine Forum. The joint venture will obtain further data of the vaccine from larger subject groups
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.